@itsmevon49's Wegovy week 4 update, fact-checked

What did @itsmevon49 actually say?

She posted her week-four Wegovy update a day late because she missed her injection window. Her immediate response: panic, then calm. "It is what it is," she said, and moved on. She reported losing roughly two kilograms over the month, attributed it to reduced food cravings, better sleep, and more movement, and framed the drug explicitly as "just a tool" that requires changing your relationship with food. She also mentioned going through menopause and described Wegovy cutting what she called "food noise," particularly evening sugar cravings. Her core advice to followers was simple: relax, adjust your mindset, and don't expect the injection alone to do all the work.

Does the science back this up?

Largely, yes. The "tool not a magic fix" framing is one of the more honest things a GLP-1 user has said on TikTok. Clinical data consistently shows that lifestyle changes amplify semaglutide's effects, and that outcomes drop when patients stop without maintaining habits.

On the missed dose specifically: Novo Nordisk's prescribing guidance states that if more than five days have passed since a missed weekly dose, skip it and resume on the regular schedule. If fewer than five days, take it as soon as possible. She was 24 hours late, well within the acceptable window. The pharmacokinetics of semaglutide support this: the drug has a half-life of approximately one week, meaning a single day's delay produces a negligible dip in plasma concentration. Davies et al. (2021, Diabetes Care) confirmed that once-weekly dosing produces stable steady-state levels that tolerate minor timing variation without clinical consequence.

Her weight loss of roughly two kilograms in four weeks sits at the lower end of what STEP 1 trial participants experienced in early weeks, but weight loss is non-linear and individual variation is well-documented (Wilding et al., 2021, New England Journal of Medicine).

What did they get wrong (or right)?

She got a lot right. The "tool" framing is accurate and clinically supported. Semaglutide works primarily by slowing gastric emptying, suppressing appetite via GLP-1 receptor agonism in the hypothalamus, and reducing food-reward signaling. It does not rewrite your diet for you. The STEP 1 trial made this explicit: participants who combined the drug with behavioral intervention lost significantly more weight than those without structured support.

Her description of reduced "food noise" is also real. This isn't anecdote. Blundell et al. (2017, Diabetes, Obesity and Metabolism) demonstrated that semaglutide reduces appetite and food craving scores on validated measures. The menopause mention is worth noting too. Hormonal shifts during perimenopause and menopause affect appetite regulation, fat distribution, and insulin sensitivity, so her experience of heightened cravings pre-Wegovy has a biological basis.

What she glossed over: she didn't mention side effects at all. Nausea affects roughly 44% of Wegovy users in early weeks (Wilding et al., 2021). Viewers starting week four expecting smooth sailing might be surprised. That omission isn't dangerous, but it's incomplete.

What should you actually know?

Missing a single weekly dose of semaglutide by 24 hours is clinically insignificant. Do not double-dose to compensate. That is explicitly contraindicated in prescribing guidance and could increase gastrointestinal side effects without adding therapeutic benefit.

The behavioral component she describes is not optional for most people. A 2022 analysis by Rubino et al. (JAMA) found that participants who stopped semaglutide regained two-thirds of lost weight within a year when lifestyle support was withdrawn. The drug reduces appetite signals; it does not permanently alter the habits that drive eating behavior.

On menopause: if you are perimenopausal or postmenopausal and considering GLP-1 therapy, that context matters for your prescriber. Hormonal status influences metabolic rate, weight distribution, and cardiovascular risk, all of which affect how your clinician should monitor your progress. Bring it up. Do not rely on TikTok timelines to benchmark your results, including this one. Two kilograms in four weeks is fine. It might also be more or less for you, and neither outcome tells you whether the drug is working or failing.